Cardio Diagnostics to Present AI Cardiovascular Tools at National Benefits Conferences
Cardio Diagnostics Holdings will showcase AI-powered cardiovascular risk solutions at four benefits conferences in June, aiming to help employers and plan administrators reduce healthcare costs and improve workforce health.
Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
The conferences provide a platform for Cardio Diagnostics to demonstrate how its artificial intelligence-driven integrated genetic-epigenetic engine can transform cardiovascular disease prevention and detection. By leveraging proprietary AI technology, the company aims to make cardiovascular risk assessment more accessible and personalized, potentially reducing the burden of heart disease on the healthcare system and employers.
Cardiovascular disease remains the leading cause of death globally and a significant cost driver for employer-sponsored health plans. According to the American Heart Association, heart disease and stroke cost the U.S. healthcare system an estimated $363 billion annually, with indirect costs from lost productivity adding further strain. Cardio Diagnostics' solutions target early identification of at-risk individuals, enabling proactive interventions that could lower long-term costs and improve employee health outcomes.
The company's presence at these conferences underscores the growing interest in precision medicine tools for population health management. Benefits decision-makers are increasingly seeking data-driven approaches to contain healthcare spending while enhancing employee wellness. Cardio Diagnostics' offerings, including the Epi+Gen CHD test and the HeartRisk platform, provide actionable insights that can guide personalized prevention strategies.
For more information, the full press release is available at https://ibn.fm/qFRHu. Updates and news related to CDIO can be found in the company's newsroom at https://ibn.fm/CDIO.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
This announcement is based on a press release from Cardio Diagnostics Holdings. Forward-looking statements within involve risks and uncertainties, including those detailed in the company's filings with the SEC.